Summer 2027
Engineering Intern
Posted on 8/27/2026
Medtronic
10,001+ employees
Medical device maker advancing therapies
Compensation Overview
$28 - $48/hr
No H1B Sponsorship
Boston, MA, USA + 19 more
More locations: Santa Ana, CA, USA | Santa Rosa, CA, USA | Irvine, CA, USA | Mansfield, MA, USA | Mounds View, MN, USA | Tempe, AZ, USA | Memphis, TN, USA | Brooklyn Center, MN, USA | Plymouth, MN, USA | Brooklyn Park, MN, USA | Fort Worth, TX, USA | Dexter, MI, USA | North Haven, CT, USA | Lafayette, CO, USA | Minneapolis, MN, USA | Newton, MA, USA | Jacksonville, FL, USA | Eatontown, NJ, USA | Boulder, CO, USA
Remote
Interns must reside in the U.S. and work on-site at least 4 days per week.
Bachelor's, Master's
 Software Engineering (1) |
|---|
Get referred to Medtronic
See people who can refer or advise you
- Working toward a bachelor's or master's degree in Biomedical Engineering, Mechanical Engineering, Electrical Engineering, Industrial Engineering, Materials Science & Engineering, Computer Engineering, Software Engineering, Computer Science, or a related engineering discipline.
- Anticipated graduation in Winter 2027, Spring 2028, Winter 2028, or Spring 2029.
- Currently authorized to work in the United States without requiring employment sponsorship now or in the future.
- Must reside in the United States for the duration of the internship.
- Must work on-site a minimum of four days per week and participate full time, 40 hours per week.
- Must be independently mobile and able to interact with a computer and communicate with peers and coworkers.
- For baccalaureate degrees earned outside the United States, the degree must satisfy the requirements of 8 C.F.R. § 214.2(h)(4)(iii)(A).
- Participate in a full-time summer internship lasting 10-11 weeks.
- Work as part of the intern cohort from June 1 through August 13 for semester-system programs or June 14 through August 20 for quarter-system programs.
- Perform the essential functions of the assigned engineering internship role.
- Prior experience in manufacturing, operations, process improvement, industrial engineering, or product support through internships, academic projects, research, laboratory work, or relevant work experience.
- Experience with Lean Manufacturing, continuous improvement, Six Sigma methodologies, process mapping, root cause analysis, or process optimization.
- Experience analyzing operational, manufacturing, quality, or engineering data.
- Experience creating technical documentation, engineering reports, project summaries, standard work instructions, or presentations.
Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Fridley, Minnesota
Founded
1949
Get referred to Medtronic
See people who can refer or advise you
Simplify's Take
What believers are saying
- June 2026 revenue reached $9.8 billion, with 6.6% organic growth.
- Health Canada approved Affera on August 5, 2026, expanding Medtronic’s PFA footprint.
- Hugo robotic surgery cleared urologic use in December 2025, opening new hospital contracts.
What critics are saying
- August 4, 2026 brought an $88 million Covidien mesh verdict in Boston.
- About 10,350 hernia-mesh plaintiffs threaten years of discovery, appeals, and settlements.
- Cardiac Ablation Solutions drove growth; any PFA slowdown will expose Medtronic’s core weakness.
What makes Medtronic unique
- Medtronic spans cardiac, surgical, neuroscience, and diabetes devices across 150 countries.
- Affera and PulseSelect give Medtronic two pulsed-field ablation platforms in 2026.
- MiniMed’s 2026 IPO separates diabetes while preserving Medtronic’s higher-margin core.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Employee Assistance Program
Wellness Program
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Boston Scientific is the third device giant hacked since March. A cyberattack is disrupting Boston Scientific's order processing and shipping worldwide - the third device giant hit since March, after Stryker and Medtronic. Note: This post was written by Claude Fable 5. The following is a synthesis of Boston Scientific's SEC filing and public statement, and reporting from The Register, BleepingComputer, The Record, CBS News, and the Echo. Boston Scientific told investors Wednesday that a cyberattack detected the day before has caused what its SEC filing calls "a global disruption to the Company's operations" - including the ability to process and ship customer orders. The company activated its incident response protocols, brought in third-party forensics experts, and posted a statement promising updates. What it cannot yet offer is a date: "the timeline for a full restoration is not yet known." Shares fell more than 4% on Wednesday. No attacker has claimed responsibility, and a spokesperson declined to tell reporters whether ransomware was involved. The company whose boxes fill the supply room. Boston Scientific, founded in 1979 and headquartered in Marlborough, Massachusetts, is one of the largest medical device manufacturers on earth: roughly 59,000 employees, commercial operations in 127 countries, and $20.1 billion in 2025 net sales, up nearly 20% in a single year. By its own count, its products treat more than 48 million patients annually. The catalog is built around treating disease through catheters and scopes rather than open surgery. Cardiovascular devices are two-thirds of the business - $13.3 billion last year: pacemakers and defibrillators, coronary stents, the guidewires and balloons of every cath lab, plus a pair of blockbuster atrial-fibrillation franchises in the Watchman stroke-prevention implant and the Farapulse ablation system. The rest spans GI endoscopy tools, kidney-stone retrieval devices, and spinal cord stimulators for chronic pain. Alongside Medtronic, Abbott, Stryker, and Johnson & Johnson's device arm, this is one of the handful of vendors stocking hospital shelves everywhere. That reach is why the outage is a healthcare story, not just a corporate one. When the vendor supplying the cath lab can't take or fulfill orders, the problem lands on hospitals with procedures already on the calendar. What the filing says - and what it leaves open. The 8-K, filed one day after detection, is candid about operations and silent about cause: "The incident has caused, and is expected to continue to cause, disruptions and limitations of access to certain of the Company's information systems and business applications that support aspects of the Company's operations, including the ability to process and ship customer orders." Two details stand out. First, Boston Scientific filed under Item 8.01 - "Other Events" - not Item 1.05, the material-cybersecurity-incident provision the SEC added in 2023, and the filing says the company "has not yet determined whether the incident is reasonably likely to have a material impact." Medtronic made a similar call in April, disclosing its breach under a voluntary item. Going public on day one while deferring the materiality question is faster than most companies manage - and pragmatic, since a stalled order pipeline is visible to customers immediately. Second, what's absent. Medtronic's April disclosure drew an explicit boundary: products, patient safety, manufacturing, and distribution were declared unaffected, running on separate networks. Boston Scientific's filing draws no such line - distribution is precisely what's down. In Ireland, where the company employs more than 7,000 people across plants in Cork, Clonmel, and Galway, day-shift workers went home with pay on Wednesday and other sites offered staff leave, according to the Echo. An email from chief information officer Charlene Stoessel told employees who can work from home to "do so while investigation and recovery efforts continue." The Record, citing CNBC, reported that investors have been told recovery could take weeks. Three giants in six months. Boston Scientific is the third major device maker attacked this year, and each incident has worn a different face. | Company | Disclosed | What happened | Who did it | | Stryker | March 11 | Destructive wiper; group claimed 200,000+ systems erased; recovery took weeks | Handala, linked to Iran | | Medtronic | April 24 | Corporate-IT data breach; 3.8 million people later notified | ShinyHunters | | Boston Scientific | August 26 | Operations outage disrupting order processing and shipping | No claim yet | Destruction, data extortion, and now an outage of undisclosed cause. The pattern isn't one actor or one technique - it's one industry. Medtech combines deep pockets, global just-in-time logistics, and products whose delay is measured in postponed procedures. That operational urgency is exactly the leverage attackers of every stripe monetize. What hospitals can do this week. A few practical moves for health systems that buy from Boston Scientific - which is most of them: * Count what you have. Check par levels on its consumables and implants, and flag lines with no drop-in substitute: a Watchman case needs Watchman hardware, and an EP lab standardized on one ablation platform can't switch overnight. * Call the rep. Ask what's already sitting in regional distribution, which pending orders will move, and whether allocation is coming for constrained product lines. * Line up alternatives early. For time-sensitive cases, decide now which vendor-equivalent devices are clinically acceptable rather than deciding the morning of a procedure. * Tighten the vendor seam. Until scope is known, apply heightened scrutiny to remote-access connections and integrations tied to the vendor, and warn staff to expect phishing themed on the incident - a supplier outage is a ready-made pretext. * Watch the open questions. Whether data was taken, whether ransomware was involved, and whether anything beyond business systems is affected all remain unanswered. Updates are promised on the company's newsroom page. Stryker's March disruption was measured in weeks of downtime. Medtronic's ran quieter but longer - its tail was 3.8 million breach-notification letters months afterward. Which clock Boston Scientific is on should start becoming clear within days. Hospitals should watch both.
Bank of America has maintained a Buy rating on Medtronic with a $95 price target, citing expectations for strong fiscal first-quarter results when the medical-device maker reports on 1 September. The company finished fiscal 2026 with $9.8 billion in fourth-quarter revenue, up 6.6% organically. Medtronic's Cardiac Ablation Solutions division posted 78% global revenue growth and 124% growth in the US, gaining eight percentage points of market share. Bank of America analyst Travis Steed expects similar growth rates to continue, potentially pushing results toward the upper end of management's 6% to 6.5% organic revenue growth guidance. However, concerns remain about sustaining momentum. Bank of America estimates CAS currently adds about three percentage points to total growth, making an eventual slowdown significant.
Building the future of Ambulatory Surgery Centers. * 08.19.2026 * by Corazon * CAT: ASC Ambulatory Surgery Centers (ASCs) continue to reshape the healthcare landscape. As more procedures migrate from hospitals to outpatient settings, ASCs are becoming a strategic priority for health systems, physicians, and investors seeking to improve patient access, reduce costs, and deliver high-quality care in a more efficient environment. But ASC success requires more than a facility and a business plan. Organizations must navigate complex decisions around market strategy, physician alignment, facility planning, regulatory readiness, accreditation, and operational performance. The ASC Opportunity Is Growing Advances in technology, anesthesia, and minimally invasive procedures continue to expand the range of cases that can safely be performed in an ASC. At the same time, employers, payers, and patients are driving demand for lower-cost, high-value sites of care. Today, cardiovascular, electrophysiology (EP), spine, and vascular procedures represent some of the fastest-growing areas of ASC expansion. For healthcare organizations, the question is no longer whether care will continue to migrate to the outpatient setting. The question is how to position for growth. As Corazon often says: Don't fight the migration. Own it. Partner in it. Influence it. From Strategy to Optimization: Corazon's ASC Expertise Through its strategic partnership with Medtronic, Corazon provide comprehensive ASC consulting services that support organizations at every stage of the ASC journey. Whether you're: * Evaluating a new ASC opportunity * Converting an office-based lab (OBL) to an ASC * Expanding cardiovascular services into the outpatient setting * Optimizing an existing ASC's performance Corazon and Medtronic deliver expertise in market assessments, business planning, financial modeling, operational readiness, accreditation preparation, patient access optimization, and regulatory navigation. Raising the Bar for Cardiovascular ASCs As cardiovascular procedures continue moving to the ASC environment, quality oversight and clinical readiness have never been more important. That's why Corazon developed its ASC Cardiovascular Accreditation Program in collaboration with the Society for Cardiovascular Angiography & Interventions (SCAI). The accreditation is specifically designed for ASCs performing cardiovascular procedures and is aligned with interventional cardiology best practices. The program evaluates: * Patient selection and risk criteria * Physician credentials and competency * Staff training and emergency preparedness * Policies, governance, and protocols * Outcomes measurement and quality oversight Organizations that achieve accreditation demonstrate a commitment to safe, high-quality cardiovascular care while strengthening credibility with physicians, payers, partners, and patients. Looking Ahead The next wave of ASC growth is already underway. Healthcare organizations that align strategy, operations, quality, and physician engagement today will be best positioned to thrive tomorrow. At Corazon, Corazon is proud to help organizations navigate every stage of the ASC journey, from feasibility and development to optimization and accreditation. Through its collaboration with Medtronic and its partnership with SCAI, Corazon is committed to advancing the future of outpatient care and helping providers build high-performing ASCs prepared for what's next.
Craif raises $33M to accelerate introduction of its urine-based cancer test to the U.S. * 4 hrs ago SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, today announced the close of its approximately $33 million* Series D, bringing total capital raised since the company's founding to roughly $88 million**. Craif will use the proceeds to strengthen its U.S. R&D, prepare for a reimbursement-driven launch of its non-invasive cancer test in the United States and advance its Japanese regulatory filing for a software-based medical device program targeting pancreatic cancer diagnosis. The financing was co-led by Granite-Integral, a joint venture between Granite Asia and Integral Corporation, and by Tauns Co., Ltd., one of Japan's largest makers of rapid diagnostic tests. Granite Asia is a Singapore-based investment platform managing about $10 billion across the Asia-Pacific region. Integral Corporation manages approximately $3 billion and was the first Japanese private equity firm to list on the Tokyo Stock Exchange. U.S. based Unreasonable and existing investor X&KSK also participated, alongside institutional and individual investors across Singapore, the United States and Japan. The round comprised approximately $30.7 million in equity and approximately $3.3 million in debt. Founded in Japan in 2018, Craif developed a urine-based cancer detection platform that uses artificial intelligence to analyze microRNA, small regulatory molecules whose discovery and biological significance were recognized by the 2024 Nobel Prize in Physiology or Medicine. Its flagship test, miSignal, is offered at more than 2,500 medical institutions and 4,500 pharmacies across Japan, with over 110,000 tests performed to date. Craif has published more than 90 peer-reviewed papers and conference presentations, including two independent publications demonstrating the early and accurate detection of pancreatic cancer. A clinical team built for the American market A key component of Craif's plans is scaling R&D at its newly opened San Diego laboratory, including a prospective clinical study of its urine-based test in pancreatic cancer. This is an indication where the clinical utility and the path to reimbursement are clear. A simple, non-invasive urine test could help clinicians decide who needs further workup and who can safely wait. To spearhead that work, Craif has appointed Nicholas (Nick) Bevins, MD, PhD, as chief medical officer. Dr. Bevins will lead the company's clinical development strategy to build the body of evidence necessary to meet reimbursement and regulatory requirements. Dr. Bevins holds a bachelor's degree in biochemistry from Columbia University, an MD and a PhD in neuroscience from the University of California, San Diego, and completed a residency in clinical pathology and laboratory medicine. He has published more than 40 peer-reviewed papers and abstracts. He is a board-certified clinical pathologist and has served as both chief medical officer and CLIA laboratory director at several biotechnology and diagnostics companies. Because offering laboratory-developed tests in the United States requires a CLIA-certified laboratory under the oversight of a qualified laboratory director, Dr. Bevins brings a rare combination of that qualification and executive responsibility for clinical and regulatory strategy. His appointment further accelerates Craif's strategic expansion as it now advances partnerships with 30 medical institutions across 15 states. The company established a U.S. subsidiary in 2022 and joined the JLABS incubator. In April 2026, Craif opened its bio-AI laboratory in San Diego, and CEO Ryuichi Onose relocated there to lead the U.S. business. Chief Financial Officer Takeo Mukai, who previously held finance and operating leadership roles at Medtronic and several U.S. healthcare companies, also joined this year as a local hire. Quote from Ryuichi Onose, CEO and co-founder, Craif "We started Craif in 2018 to solve cancer, a problem the whole world shares, with technology built in Japan. We have brought our test to more than 2,500 clinics at home, and we are approaching a regulatory filing in pancreatic cancer. I moved to San Diego to build our U.S. business myself, because the United States is the hardest and most important market to prove this technology. What we are building goes beyond a single cancer test. The earliest signals of many diseases show up in urine, and reading them is what Craif is really about. Cancer is the first step." Quote from Nick Bevins, Chief Medical Officer "I joined Craif because the company has built a differentiated platform, generated an extraordinary body of clinical evidence in Japan, and is committed to advancing science through rigorous data rather than hype. Urine will play an increasingly important role in the future of early disease detection because it offers a non-invasive window into human biology. I look forward to collaborating with the team to make this accessible to patients." Quote from CK Chuon, Partner & Co-Head, Granite-Integral "Cancer screening should be as simple as a routine check-up, not a procedure patients avoid. Craif has proven in Japan that a non-invasive urine test can detect cancer early and at scale, and we believe the same approach can unlock massive unmet demand in the United States. We are proud to co-lead this round as Craif brings that vision to the world's largest healthcare market." Quote from Masataka Nonaka, President & Representative Director, TAUNS Laboratories, Inc. "Serving as a co-lead investor in Craif's Series D means a great deal to Mycarrollcountynews. This round will accelerate Craif's R&D, its clinical development toward regulatory approval and its global expansion. As one of Craif's distribution partners for miSignal, Mycarrollcountynews also expect the funding to move both miSignal and the pancreatic cancer SaMD program now in development closer to real-world clinical use. Craif's urine microRNA analysis technology opens new possibilities in early cancer detection and more precise diagnosis, and Mycarrollcountynews want to see it reach as many patients and healthcare institutions as possible. TAUNS will continue to support Craif's growth over the long term. Through its partnership, Mycarrollcountynews intend to help bring next-generation diagnostics into practice and contribute to solving healthcare challenges in Japan and around the world." *Total round amount, including equity investment, financing, and the secondary transaction. ¥5.28 billion at an exchange rate of ¥160.72 = $33 million. The exchange rate used is July TTM: ¥ 160.72 per USD. **Cumulative equity investment, financing, and grants since founding. Total funding raised to date: ¥14.2 billion (approximately $88 million). About Craif Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com. Forward-looking statements This release contains forward-looking statements about Craif's plans, clinical development, regulatory timelines, and business prospects. Actual results may differ materially from those expressed or implied. Craif undertakes no obligation to update these statements except as required by law. Media inquiries Craif USA, Inc.
Medtronic faces contrasting developments after a federal jury ordered it to pay $88 million in compensatory damages over injuries linked to Covidien hernia mesh in August 2026. The verdict represents a record settlement in the ongoing litigation. Meanwhile, Medtronic Canada secured Health Canada approval for its Affera Integrated Mapping and Ablation System, designed to treat atrial fibrillation and atrial flutter. The approval gives Medtronic a second pulsed field ablation platform alongside its existing PulseSelect system. The company's investment narrative projects $41.5 billion in revenue and $6.6 billion in earnings by 2029, requiring 4.5% annual revenue growth. Analysts estimate a fair value of $98.00, representing a 7% upside from current levels. However, cautious analysts forecast lower revenue of around $38.6 billion and earnings of approximately $6.2 billion by 2029, citing concerns over legal exposure and execution risks.